Equity Profile

CRNX

Crinetics Pharmaceuticals, Inc.

Health CarePharmaceuticals$9.0B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses this quarter.

$-1.06

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$16M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases. With a market cap of $9 billion, it plays a significant role in the pharmaceuticals industry, particularly in addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q1-2026, Crinetics reported an EPS of $-1.23, slightly missing estimates but showing a modest stock increase of 4.27% the following day. The company did not provide specific revenue figures for that quarter.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Crinetics to report a loss of $-1.06 per share on $16 million in revenue for Q2-2026. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If Crinetics can exceed earnings expectations and show signs of revenue growth, it could signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company reports wider losses or stagnant revenue, it may raise concerns about its long-term viability and lead to a sell-off.

Key Metrics to Watch

EPS

$-1.06

Earnings per share is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses this quarter.

Revenue

$16M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-1.06?

A narrower loss could indicate improved operational efficiency and boost investor sentiment.

What are the revenue figures compared to the expected $16 million?

Revenue performance will be critical in assessing market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for Crinetics to narrow its losses this quarter, as recent operational improvements could lead to better-than-expected results.

Supporting Evidence

The stock has historically reacted positively even with EPS misses, indicating resilience.

The options market is pricing in a significant move, suggesting that investors expect surprises.

Previous quarters have shown that even small improvements can lead to notable stock gains.

Key Risk

If the EPS loss is significantly narrower than expected, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it could indicate whether Crinetics is on a path to recovery or facing deeper challenges.

Bull Confirmed If

Reporting an EPS loss narrower than $-1.06 and revenue exceeding $16 million would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.06 and revenue below $16 million would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.7%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around 1.42%, confirming a positive outlook.

In-Line / Cautious

An in-line result may lead to a muted response, as investors await further commentary from management.

Miss

If the company misses expectations, history suggests a potential decline of around 1.90%, raising concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements or regulatory approvals.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for current and upcoming therapies.
4Discussion of any strategic partnerships or collaborations.
5Any guidance on future revenue expectations or financial outlook.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses this quarter.

$-1.06

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$16M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Crinetics to report a loss of $-1.06 per share on $16 million in revenue for Q2-2026. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If Crinetics can exceed earnings expectations and show signs of revenue growth, it could signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company reports wider losses or stagnant revenue, it may raise concerns about its long-term viability and lead to a sell-off.

Key Metrics to Watch

EPS

$-1.06

Earnings per share is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses this quarter.

Revenue

$16M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-1.06?

A narrower loss could indicate improved operational efficiency and boost investor sentiment.

What are the revenue figures compared to the expected $16 million?

Revenue performance will be critical in assessing market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for Crinetics to narrow its losses this quarter, as recent operational improvements could lead to better-than-expected results.

Supporting Evidence

The stock has historically reacted positively even with EPS misses, indicating resilience.

The options market is pricing in a significant move, suggesting that investors expect surprises.

Previous quarters have shown that even small improvements can lead to notable stock gains.

Key Risk

If the EPS loss is significantly narrower than expected, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it could indicate whether Crinetics is on a path to recovery or facing deeper challenges.

Bull Confirmed If

Reporting an EPS loss narrower than $-1.06 and revenue exceeding $16 million would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.06 and revenue below $16 million would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.7%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around 1.42%, confirming a positive outlook.

In-Line / Cautious

An in-line result may lead to a muted response, as investors await further commentary from management.

Miss

If the company misses expectations, history suggests a potential decline of around 1.90%, raising concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements or regulatory approvals.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for current and upcoming therapies.
4Discussion of any strategic partnerships or collaborations.
5Any guidance on future revenue expectations or financial outlook.